In vitro 3D colon tumor penetrability of SRJ09, a new anti-cancer andrographolide analog

Charng Choon Wong, Nagarajan Periasamy, Sreenivasa Rao Sagineedu, Shiran Sidik, Shariful Hasan Sumon, Paul Loadman, Roger Phillips, Nordin Haji Lajis, Johnson Stanslas

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Limited tumor penetrability of anti-cancer drugs is recognized as one of the major factors that lead to poor antitumor activity. SRJ09 (3,19-(2-bromobenzylidene) andrographolide) has been identified as a lead anti-cancer agent for colon cancer. Recently, this compound was shown by us to be a mutant K-Ras binder. In this present study, the penetrability of SRJ09 through the DLD-1 colon cancer multicell layer (MCL) was evaluated. The amount of SRJ09 that penetrated through the MCL was quantitated by utilizing high performance liquid chromatography (HPLC). Histopathological staining was used to visualize the morphology of MCL. A chemosensitivity assay was performed to assess the anticancer activity of SRJ09 in DLD-1 cells. SRJ09 was able to penetrate through DLD-1 MCL and is inversely proportional with the MCL thickness. The flow rates for SRJ09 through MCL were 0.90±0.20 μM/min/cm2 and 0.56±0.06 μM/min/cm2 for days 1 and 5, respectively, which are better than doxorubicin. Histopathological examination revealed that the integrity of the DLD-1 MCL was retained and no visible damage was inflicted on the cell membrane, confirming the penetration of SRJ09 was by diffusion. Short term exposure (1 h) in DLD-1 cells demonstrated SRJ09 had IC50 of 41 μM which was approximately 4-folds lower than andrographolide, the parent compound of SRJ09. In conclusion, SRJ09 successfully penetrated through DLD-1 MCL by diffusion and emerged as a potential candidate to be developed as a clinically viable anti-colon cancer drug.

Original languageEnglish
Pages (from-to)806-814
Number of pages9
JournalInvestigational New Drugs
Volume32
Issue number5
Early online date31 May 2014
DOIs
Publication statusPublished - Oct 2014
Externally publishedYes

Fingerprint

Colonic Neoplasms
Colon
Neoplasms
Pharmaceutical Preparations
Doxorubicin
Inhibitory Concentration 50
High Pressure Liquid Chromatography
Cell Membrane
Staining and Labeling
In Vitro Techniques
andrographolide
3,19-(2-bromobenzylidene)andrographolide

Cite this

Wong, C. C., Periasamy, N., Sagineedu, S. R., Sidik, S., Sumon, S. H., Loadman, P., ... Stanslas, J. (2014). In vitro 3D colon tumor penetrability of SRJ09, a new anti-cancer andrographolide analog. Investigational New Drugs, 32(5), 806-814. https://doi.org/10.1007/s10637-014-0105-6
Wong, Charng Choon ; Periasamy, Nagarajan ; Sagineedu, Sreenivasa Rao ; Sidik, Shiran ; Sumon, Shariful Hasan ; Loadman, Paul ; Phillips, Roger ; Lajis, Nordin Haji ; Stanslas, Johnson. / In vitro 3D colon tumor penetrability of SRJ09, a new anti-cancer andrographolide analog. In: Investigational New Drugs. 2014 ; Vol. 32, No. 5. pp. 806-814.
@article{8d0878b204cb4eccbbeff8d9c202d061,
title = "In vitro 3D colon tumor penetrability of SRJ09, a new anti-cancer andrographolide analog",
abstract = "Limited tumor penetrability of anti-cancer drugs is recognized as one of the major factors that lead to poor antitumor activity. SRJ09 (3,19-(2-bromobenzylidene) andrographolide) has been identified as a lead anti-cancer agent for colon cancer. Recently, this compound was shown by us to be a mutant K-Ras binder. In this present study, the penetrability of SRJ09 through the DLD-1 colon cancer multicell layer (MCL) was evaluated. The amount of SRJ09 that penetrated through the MCL was quantitated by utilizing high performance liquid chromatography (HPLC). Histopathological staining was used to visualize the morphology of MCL. A chemosensitivity assay was performed to assess the anticancer activity of SRJ09 in DLD-1 cells. SRJ09 was able to penetrate through DLD-1 MCL and is inversely proportional with the MCL thickness. The flow rates for SRJ09 through MCL were 0.90±0.20 μM/min/cm2 and 0.56±0.06 μM/min/cm2 for days 1 and 5, respectively, which are better than doxorubicin. Histopathological examination revealed that the integrity of the DLD-1 MCL was retained and no visible damage was inflicted on the cell membrane, confirming the penetration of SRJ09 was by diffusion. Short term exposure (1 h) in DLD-1 cells demonstrated SRJ09 had IC50 of 41 μM which was approximately 4-folds lower than andrographolide, the parent compound of SRJ09. In conclusion, SRJ09 successfully penetrated through DLD-1 MCL by diffusion and emerged as a potential candidate to be developed as a clinically viable anti-colon cancer drug.",
keywords = "Andrographolide analogue, Coloncancer, DLD-1, Multi cell layer, Tumor penetration",
author = "Wong, {Charng Choon} and Nagarajan Periasamy and Sagineedu, {Sreenivasa Rao} and Shiran Sidik and Sumon, {Shariful Hasan} and Paul Loadman and Roger Phillips and Lajis, {Nordin Haji} and Johnson Stanslas",
note = "No full text in Eprints. HN 29/11/2017",
year = "2014",
month = "10",
doi = "10.1007/s10637-014-0105-6",
language = "English",
volume = "32",
pages = "806--814",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "5",

}

Wong, CC, Periasamy, N, Sagineedu, SR, Sidik, S, Sumon, SH, Loadman, P, Phillips, R, Lajis, NH & Stanslas, J 2014, 'In vitro 3D colon tumor penetrability of SRJ09, a new anti-cancer andrographolide analog', Investigational New Drugs, vol. 32, no. 5, pp. 806-814. https://doi.org/10.1007/s10637-014-0105-6

In vitro 3D colon tumor penetrability of SRJ09, a new anti-cancer andrographolide analog. / Wong, Charng Choon; Periasamy, Nagarajan; Sagineedu, Sreenivasa Rao; Sidik, Shiran; Sumon, Shariful Hasan; Loadman, Paul; Phillips, Roger; Lajis, Nordin Haji; Stanslas, Johnson.

In: Investigational New Drugs, Vol. 32, No. 5, 10.2014, p. 806-814.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vitro 3D colon tumor penetrability of SRJ09, a new anti-cancer andrographolide analog

AU - Wong, Charng Choon

AU - Periasamy, Nagarajan

AU - Sagineedu, Sreenivasa Rao

AU - Sidik, Shiran

AU - Sumon, Shariful Hasan

AU - Loadman, Paul

AU - Phillips, Roger

AU - Lajis, Nordin Haji

AU - Stanslas, Johnson

N1 - No full text in Eprints. HN 29/11/2017

PY - 2014/10

Y1 - 2014/10

N2 - Limited tumor penetrability of anti-cancer drugs is recognized as one of the major factors that lead to poor antitumor activity. SRJ09 (3,19-(2-bromobenzylidene) andrographolide) has been identified as a lead anti-cancer agent for colon cancer. Recently, this compound was shown by us to be a mutant K-Ras binder. In this present study, the penetrability of SRJ09 through the DLD-1 colon cancer multicell layer (MCL) was evaluated. The amount of SRJ09 that penetrated through the MCL was quantitated by utilizing high performance liquid chromatography (HPLC). Histopathological staining was used to visualize the morphology of MCL. A chemosensitivity assay was performed to assess the anticancer activity of SRJ09 in DLD-1 cells. SRJ09 was able to penetrate through DLD-1 MCL and is inversely proportional with the MCL thickness. The flow rates for SRJ09 through MCL were 0.90±0.20 μM/min/cm2 and 0.56±0.06 μM/min/cm2 for days 1 and 5, respectively, which are better than doxorubicin. Histopathological examination revealed that the integrity of the DLD-1 MCL was retained and no visible damage was inflicted on the cell membrane, confirming the penetration of SRJ09 was by diffusion. Short term exposure (1 h) in DLD-1 cells demonstrated SRJ09 had IC50 of 41 μM which was approximately 4-folds lower than andrographolide, the parent compound of SRJ09. In conclusion, SRJ09 successfully penetrated through DLD-1 MCL by diffusion and emerged as a potential candidate to be developed as a clinically viable anti-colon cancer drug.

AB - Limited tumor penetrability of anti-cancer drugs is recognized as one of the major factors that lead to poor antitumor activity. SRJ09 (3,19-(2-bromobenzylidene) andrographolide) has been identified as a lead anti-cancer agent for colon cancer. Recently, this compound was shown by us to be a mutant K-Ras binder. In this present study, the penetrability of SRJ09 through the DLD-1 colon cancer multicell layer (MCL) was evaluated. The amount of SRJ09 that penetrated through the MCL was quantitated by utilizing high performance liquid chromatography (HPLC). Histopathological staining was used to visualize the morphology of MCL. A chemosensitivity assay was performed to assess the anticancer activity of SRJ09 in DLD-1 cells. SRJ09 was able to penetrate through DLD-1 MCL and is inversely proportional with the MCL thickness. The flow rates for SRJ09 through MCL were 0.90±0.20 μM/min/cm2 and 0.56±0.06 μM/min/cm2 for days 1 and 5, respectively, which are better than doxorubicin. Histopathological examination revealed that the integrity of the DLD-1 MCL was retained and no visible damage was inflicted on the cell membrane, confirming the penetration of SRJ09 was by diffusion. Short term exposure (1 h) in DLD-1 cells demonstrated SRJ09 had IC50 of 41 μM which was approximately 4-folds lower than andrographolide, the parent compound of SRJ09. In conclusion, SRJ09 successfully penetrated through DLD-1 MCL by diffusion and emerged as a potential candidate to be developed as a clinically viable anti-colon cancer drug.

KW - Andrographolide analogue

KW - Coloncancer

KW - DLD-1

KW - Multi cell layer

KW - Tumor penetration

UR - http://www.scopus.com/inward/record.url?scp=84930729197&partnerID=8YFLogxK

U2 - 10.1007/s10637-014-0105-6

DO - 10.1007/s10637-014-0105-6

M3 - Article

VL - 32

SP - 806

EP - 814

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 5

ER -